ВНУТРИПУЗЫРНАЯ ТЕРАПИЯ РАКА МОЧЕВОГО ПУЗЫРЯ: СОВРЕМЕННОЕ СОСТОЯНИЕ ПРОБЛЕМЫ

Внутрипузырная химио-/иммунотерапия является составной частью комплексного лечения рака мочевого пузыря и широко применяется после трансуретральной резекции опухоли. Цель интравезикальной терапии состоит в снижении риска развития рецидива и прогрессии заболевания за счет прямого цитотоксического воздействия на злокачественное новообразование. Уникальные свойства мочевого пузыря позволяют постоянно совершенствовать существующие и создавать новые методы местного лечения, такие как внутрипузырный электрофорез, локальная гипертермия, генная терапия, применение веществ-пенетрантов и магнитных частиц. Представленный обзор объединяет физико-химические свойства и фармакокинетическую характеристику лекарств, особенности гистоархитектоники мочевого пузыря, настоящее и будущее внутрипузырной терапии.

рак мочевого пузыря, внутрипузырная терапия, иммунотерапия, химиотерапия

1. Чиссов В.И., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2007 году. М., 2009.

2. Rene N.J., Cury F.B., Souhami L. Conservative treatment of invasive bladder cancer. Curr Oncol 2009;16(4): 36–47.

3. American Cancer Society. Cancer facts and figures. American Cancer Society, Atlanta, GA, 2007.

4. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55(2):74−108.

5. Simons M.P., O’Donnell M.A., Griffith T.S. Role of neutrophils in BCG immunotherapy for bladder cancer. Urol Oncol; 2008 Jul-Aug; 26(4):341–5.

6. Матвеев Б.П. и др. Клbladder cancer, intravesical therapy, immunotherapy, chemotherapyиническая онкоурология. М., 2003. 7. Schenk-Braat E.A., Bangma C.H. Immunotherapy for superficial bladder cancer. Cancer Immunol Immunother. 2005; 54(5):414−23.

7. Jalón Monzón A., Fernández Gómez J.M., Escaf Bramada S. et al.Therapeutic effect of immediate postoperative mitomycin C in patients with low-risk non-muscle-invasive bladder tumors. Actas Urol Esp 2008;32(8):811−20.

8. Hicks R.M., Ketterer В., Warren R.C. Isolation and characterization of the urothelial lumenal plasma membrane J Cell Biol 1977;73(2): 382–99.

9. De Bruijn E.A., Sleeboom H.P., van Helsdingen P.J. et al. Pharmacodynamics and pharmacokinetics of intravesical mitomycin C upon different dwelling times. Int J Cancer 1992;51(3):359−64.

10. Chai M., Wientjes M.G., Badalament R.A. et al. Pharmacokinetics of intravesical doxorubicin in superficial bladder cancer patients. J Urol 1994; 152(2 Pt 1):374−8.

11. Song D., Wientjes M.G., Au J.L. Bladder tissue pharmacokinetics of intravesical taxol. Cancer Chemother Pharmacol 1997;40(4):285−92.

12. Kirkali Z., Chan T., Manoharan M. et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005;66 (6 Suppl 1):4−34. 14. Underberg W. J., Lingeman H. Aspects of the chemical stability of mitomycin and porfiromycin in acidic solution. J. Pharm Sci 1983; 72(5):549−53.

13. See W.A., Xia Q. Regional chemotherapy for bladder neoplasms using continuous intravesical infusion of doxorubicin: impact of concomitant administration of dimethyl sulfoxide on drug absorption and antitumor activity. J Natl Cancer Inst 1992;84(7):510−5.

14. Ilett K.F., Ong R.T., Batty K.T., Taylor J.D. Effect of urine pH on the stability of doxorubicin and its recovery from bladder instillations. Br J Urol 1990; 65(5):478−82.

15. Harris N.M., Duffy P.M., Crook T.J. et al. Intravesical pH: a potentially important variable affecting efficacy and the further development of anthracycline chemotherapy for superficial bladder cancer. BJU Int 2002; 90(9):957−64.

16. Grabnar I., Bogataj M., Belic A. et al. Kinetic model of drug distribution in the urinary bladder wall following intravesical instillation. Int J Pharmac 2006; 322(1−2):52−9.

17. Shen Z., Shen T., Wientjes M.G. et al. Intravesical treatments of bladder cancer: review. Pharm Res 2008; 25(7):1500−10.

18. Mellett J.B., Woods L.A. The comparative physiological disposition of thiotepa and tepa in the dog. Cancer Res1960;20:524–32.

19. Morales A., Eidinger D., Bruce A.W. Intracavitary Ba cillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976;116(2):180−3.

20. Alexandroff A.B., Jackson A.M., O’Donnell M.A., James K. BCG immunotherapy of bladder cancer: 20 years on. Lancet; 1999;353(9165):1689−94.

21. Sylvester R.J., van der Meijden A.P., Lamm D.L. In travesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002; 168(5):1964−70.

22. Han R.F., Pan J.G. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 2006;67(6):1216−23.

23. Witjes J.A., Hendricksen K. Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analy sis of currently available drugs, treatment schedules, and longterm results. Eur Urol 2008;53(1):45−52.

24. Smaldone M.C., Gingrich J.R. Immunotherapeutic agents for the management of BCG refractory non-muscle invasive bladder cancer. Minerva Urol Nefrol 2010; 62(2):129−32.

25. Babjuk M., Oosterlinck W., Sylvester R. et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the blad der. Eur Urol 2008; 54(2):303−14.

26. Malkowicz S.B. The role of intravesical chemotherapy in the treatment of bladder cancer. In: S. P. Lerner, M. Schoenberg, C. Sternberg (eds.). Textbook of Bladder Cancer, Informa Healthcare, London, 2006; p. 335–340.

27. Nilsson S., Ragnhammar P., Glimelius B., Nygren P.; SBU-group. Swedish Council of Technology As sessment in Health Care. A systematic overview of chemotherapy effects in urothelial bladder cancer. Acta Oncol 2001;40(2−3):371−90.

28. Bartoletti R., Cai T., Gacci M. et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a phase II prospective multicenter study. Urology 2005;66(4):726−31.

29. Dalbagni G., Russo P., Bochner B. et al. Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder. J Clin Oncol 2006; 24(18):2729−34.

30. Серегин И.В., Самойленко В.М., Фигурин К.М. Внутрипузырное применение гемцитабина у больных поверхностным раком мочевого пузыря, резистентным к внутрипузырной иммунотерапии вакциной БЦЖ. Онкоурология 2005;(2):32−3.

31. Grossman B.H., O’Donnell M.A., Cookson M.S. et al. Bacillus Calmette-Guerin Failures and Beyond: contemporary management of non-muscle-invasive bladder. Cancer Rev Urol 2008;10(4):281−9.

32. Steinberg G., Bahnson R., Brosman S. et al. Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guérin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol 2000;163(3):761−7.

33. Sylvester R.J., van der Meijden A.P., Witjes J.A., Kurth K. Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 2005;174(1):86−91.

34. Böhle A., Jocham D., Bock P.R. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003;169(1):90−5.

35. Shelley M.D., Wilt T.J., Court J. et al. Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 2004;93(4):485−90.

36. Böhle A., Bock P.R. Intravesical bacilli Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal metaanalysis of comparative studies on tumor progression. Urology 2004; 63(4):682−6.

37. Sylvester R.J. Natural history, recurrence, and progres sion in superficial bladder cancer. Scientific World Journal 2006; 6:2617−25.

38. Sylvester R.J., Oosterlinck W., van der Meijden A.P. A single immediate postoperative instillation of chemo therapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004;171(6 Pt 1):2186−90.

39. Hall M.C., Chang S.S., Dalbagni G. et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007;178(6):2314−30.

40. Chen D., Song D., Wientjes M.G., Au J.L. Effect of dimethyl sulfoxide on bladder tissue penetration of intravesical paclitaxel. Clin Cancer Res 2003; 9(1):363−9.

41. Grabnar I., Bogataj M., Mrhar A. Influence of chitosan and polycarbophil on permeation of a model hydrophilic drug into the urinary bladder wall. Int J Pharm 2003; 256(1−2):167−73.

42. Hobarth K., Maier U., Marberger M. Topical chemoprophylaxis of superficial bladder cancer with mitomycin C and adjuvant hyaluronidase. Eur Urol 1992; 21(3):206−10.

43. Lokeshwar V.B., Estrella V., Lopez L. et al. HYAL1-v1, an alternatively spliced variant of HYAL1 hyaluronidase: a negative regulator of bladder cancer. Cancer Res 2006;66(23):11219−27.

44. Visage C.Le, Rioux-Leclercq N., Haller M. et al. Efficacy of paclitaxel released from bioadhesive polymer microspheres on model superficial bladder cancer. J Urol 2004;171(3):1324−9.

45. Ye Z., Chen J., Zhang X. et al. Novel gelatin-adriamycin sustained drug release system for intravesical therapy of bladder cancer. J Tongji Med Univ 2001; 21(2):145−8.

46. Leakakos T., Ji C., Lawson G. et al. Intravesical administration of doxorubicin to swine bladder using magnetically targeted carriers. Canc Chem Pharmacol 2003; 51(6):445−50.

47. Moskovitz B., Beyer M.G., Kravtzov A. et al. Thermo-chemotherapy for intermediate or high-risk recurrent superficial bladder cancer patients. Ann Oncol 2005;16(4):585−9.

48. Красный С.А., Суконко О.Г., Поляков и С.Л. др. Внутрипузырная электрохимиотерапия в лечении поверхностного рака мочевого пузыря. UroWeb.ru. http://www.uroweb.ru/db/article/942.html

49. Di Stasi S.M., Giannantoni A., Massoud R. et al. Electromotive versus passive diffusion of mitomycin C into human bladder wall: concentration- depth profiles studies. Cancer Res 1999; 59(19):4912−8.

50. Di Stasi S.M., Verri C., Capelli G. et al. Single immediate preoperative instillation of Electromotive Mitomycin-C for Primary Non-Muscle Invasive Bladder Cancer: A Randomized Prospective Trial. EUA Annual Congress — Barcelona 2010 [Abstr 196]. EAU Barcelona 2010 webcasts. http://www.eaubarcelona2010.org/?id=176&S=26273

51. Di Stasi S.M., Massoud S., Dolci S. et al. Concentration-dept profiles of Mitomycin-C in the human bladder wall after passive diffusion, termo-chemotherapy and electromotive drug administration. EUA Annual Congress — Barcelona 2010 [Abstr 196]. EAU Barcelona 2010 webcasts. http://www.eaubarcelona2010.org/?id=176&S=26274

52. Di Stasi S.M., Giannantoni A., Giurioli A. et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomized controlled trial. Lancet Oncol 2006; 7:43–51.

53. Fodor I., Timiryasova T., Denes B. et al. Vaccinia virus mediated p53 gene therapy for bladder cancer in an orthotopic murine model. J Urol 2005; 173(2):604−9.

54. Connor R.J., Anderson J.M., Machemer T. et al. Sustained intravesical interferon protein exposure is achieved using an adenoviral-mediated gene delivery system: a study in rats evaluating dosing regimens. Urology 2005; 66(1):224−9.

55. Horiguchi Y., Larchian W.A., Kaplinsky R. et al. Intravesical liposomemediated interleukin-2 gene therapy in orthotopic murine bladder cancer model. Gene Ther 2000;7(10):844−51.